Synthos Research · Health & longevity · all questions · the Conviction Board
Are GLP-1 stocks still a buy?
The science panel rates the GLP-1 story 78/100 (durable, expanding indications) while the trade sits at the 47th percentile — a Science Gap of +30: still half-priced by our measure. Expert conviction: 92/100. Our LLY and NVO deep dives carry the per-name verdicts.
Synthos Score (parent prediction): 78/100 · graded in public
Synthos Research · synthosresearch.com · as of July 6, 2026 · distilled from 53,000+ dated, attributed expert claims, weighted by verified track record · updated weeklyWant the full picture? The complete call — the dialectic, what would change our mind, and the live change-log — is on the prediction page. Track it and we'll email you the moment it moves.